Webinaires : Les Jeudis de la SFI 2022

• Welcome introduction
  Noushin Mossadegh-Keller, Vice President SFI (Marseille, France)

• 1. Harnessing a neoadjuvant clinical trial to find putative new biomarkers of response to PD-1 blockade
  Anne-Gaëlle Goubet (Agora Cancer Research Center, Lausanne, Switzerland)

• 2. Discrete role of canonical NF-kB subunits as master regulators of conventional CD4+ T cell function in response to cancer
  Guilhem Lalle (Cancer Research Center of Lyon, France - Team Y. Grinberg-Bleyer)

• 3. Nociceptive sensory neurons promote CD8 T cell responses to HSV-1 infection
  Anaïs Roger (CIML, Marseille, France - Team S. Ugolini)

• Miltenyi Biotec

• 1. Interféron et anti-interféron dans le lupus : ce que nous apprend la clinique
  Alexis Mathian (Paris)

• 2. Traitements actuels et futurs
  Laurent Arnaud (Strasbourg)

• 3. Nephropathie lupique
  Noémie Jourde-Chiche (Marseille)

• 1. Mesenchymal stromal cells: from basic concepts to functional characterizations in normal and lymphoma settings
  Frédéric Mourcin (U1236, Rennes)

• 2. Role of stromal heterogeneity in immunosuppression and resistance to immunotherapy in cancer
  Fatima Mechta-Grigoriou (Institut Curie, Paris)

• 10x Genomics
   How it Works | Chromium Single Cell Immune Profiling Solution

• Beckman Coulter
   Anis Larbi

• 1. The interleukin-36 cytokines family and their role in driving skin and joint inflammation
  Marie-Astrid Boutet (Nantes)

• 2. De l’immunogénétique aux traitements ciblés : contribution d’une dérégulation de la voie de l’interleukine-36 dans les pathologies inflammatoires
  Hervé Bachelez (Paris)

• 1. Ingénierie des régions constantes parmi les anticorps approuvés en clinique
  Hervé Watier (Tours)

• 2. Recyclage des anticorps : ingénierie et conséquences fonctionnelles
  Valérie Gouilleux (Tours)

• 3. Anticorps bispécifiques approuvés en clinique : de multiples potentialités
  Thierry Chardès (Montpellier)

Presentation

• Welcome introduction
  Noushin Mossadegh-Keller (Marseille)

• NK cells biology and therapeutic opportunities
  Eric Vivier (Marseille)

Give voice to the partners

• Innate Pharma
  Yannis Morel

• Beckman Coulter
  Anis Larbi

Agilent
Pascale Daou

• 1. Risque infectieux des voies respiratoires basses des patients sous immunosuppresseurs
  Claire Aguilar (Paris)

• 2. Niveau de protection des patients sous immunosuppresseurs en France
  Benjamin Wyplosz (Paris)

• 3. Efficacité vaccinale des patients sous immunosuppresseurs
  Anne Conrad (Lyon)

• 4. Table ronde
  

Presentations

• Hormonal regulation of ILC2 in allergic respiratory diseases
  Sophie Laffont-Pradines (Toulouse)

• Development of therapeutic vaccines for the treatment of allergic diseases
  Laurent Reber (Toulouse)

• 1. Using chemotherapy or Tyrosine kinase inhibitor to boost efficacy of immunotherapy
  François Ghiringhelli (Dijon)

• 2. Emergent predictive biomarkers in cancer immunotherapy
  Éric Tartour (Paris)

• 3. Questions and answers - Round table discussion
  François Ghiringhelli et Éric Tartour

Presentations

• Loss of segmented filamentous bacteria in type 1 diabetes are associated with inflammation
  Agnès Lehuen (Paris)

• Microbiota and inflammatory rheumatism
  Maxime Breban (Paris)

Give voice to the partners

Agilent

• Le NovoCyte Advanteon d’Agilent : un outil performant pour la détection, la quantification et l’analyses de micro-organismes
  Jérome Darakdjian (Agilent)

• La technologie xCELLigence RTCA pour étudier les biofilms bactériens
  Pascale Daou (Agilent)

• 1 - Hypersensibilités aux vaccins
  Frédéric Bérard (Allergologie et Immunologie Clinique, Lyon)

• 2 - Pharmacovigilance des réactions d’hypersensibilité aux vaccins COVID
  Aurore Gouraud (Pharmacovigilance, Lyon)

• 3 - Place de l’allergologue
  Isabelle Bossé (Allergologue, La Rochelle)

• 4 - Table ronde
  Frédéric Bérard, Aurore Gouraud et Isabelle Bossé

• 1. fAI2R, la filière de santé des maladies auto-immunes et auto-inflammatoires rares : actions et perspectives
  Éric Hachulla (Lille)

• 2. Immunology of autoimmune bullous skin diseases
  Vivien Hébert (Rouen)

• 3. Platelets in autoimmune diseases
  Patrick Blanco (Bordeaux)

• 4. Questions and answers - Round table discussion
  Éric Hachulla, Vivien Hébert and Patrick Blanco

Presentation

• Shaping the immune response with Chimeric Antigen Receptor (CAR) Regulatory T cells
  Julien Zuber (Paris)

• Q&A

Give voice to the partners

• BD
  BD Rhapsody single cell analysis provides new insights in immunology research
  Mohamad Kurdi, Ph.D (BD Life Sciences-Biosciences)

• Fluidigm
  The Power of Mass Cytometry in CAR-T Cell Therapies
  Émilie Gregori (Field Application Specialist, Fluidigm)

• Quanterix Corporation
  SimoA technology: Ultra-sensitive measurement of Biomarkers
  Milena Milutinovic (Quanterix)

Presentation

• B cells and Tertiary Lymphoid Structures as biomarkers of response to immune checkpoint blockade in soft-tissue sarcoma and other cancers
  Florent Petitprez (University of Edinburgh, Edinburgh, UK)

• BTN2A1 triggers the Vγ9Vδ2 T cell cytotoxicity but heterodimerization with BTN3A1 is required to potentiate their activation
  Chirine Rafia (CRICNA, Nantes, France & ImCheck Therapeutics, Marseille, France)

• Metabolic requirements of γδT cells for their effector functions in tumor microenvironments
  Noella Lopes (Instituto de Medecina Molecular, Lisbon, Portugal)

Give voice to the partners

• Cytek
  New insights about spectral cytometry by Cytek Biosciences
  Juliette Desfrancois (Cytek)

• Quanterix Corporation
  SimoA technology: Ultra-sensitive measurement of Biomarkers.
  Milena Milutinovic (Quanterix)

• 1. Clinical aspects
  Sophie Georgin-Lavialle (Paris)

• 2. Pathophysiology
  Alexandre Belot (Lyon)

• 3. Genetic and immunology diagnostic tools
  Guillaume Sarrabay (Montpellier) et Rémi Pescarmona (Lyon)

• 4. Questions and answers - Round table discussion
  Sophie Georgin-Lavialle, Alexandre Belot, Guillaume Sarrabay et Rémi Pescarmona

Presentation

• Cell therapy with human tolerogenic dendritic cells, mechanisms and clinical application
  Aurélie Moreau (Nantes)

• Q&A

Give voice to the partners

• Stemcell
  Tools for Myeloid Research
  Graeme Milton (European Market Development Manager, Immunology)

• Molecular Devices - Beckman Coulter
  Contribution of two complementary technologies in cell analysis: imaging and flow cytometry
  Guillaume Frugier (Molecular Devices)
  Anis Larbi (Beckman Coulter)

Presentation

• The defense against Covid
  Alain Fischer (Paris)

• Q&A

Give voice to the partners

• NanoString
  Map the Universe of Biology with Nanostring GeoMx DSP
  Valérie Lacoste-Mienville (NanoString)

• Bio-Rad
  Introducing StarBright Dyes
  Andrea Tradori (Bio-Rad)

Partie 1

• Réponse innée et physiopathologie
  Benjamin Terrier (Paris)

• Réponse humorale et tests sérologiques : le Yin-Yan des anticorps
  Michel Cogné (Limoges)

• Réponse cellulaire
  Amélie Guihot (Paris)

• Questions/Réponses - Table ronde
  Benjamin Terrier, Michel Cogné et Amélie Guihot

Pause

Partie 2

• Anti-inflammatoires et autres thérapies ciblées
  Xavier Mariette (Paris)

• Immunothérapies spécifiques
  Pierre Tiberghien (Besançon)

• Vaccins
  Marie-Paule Kieny (Paris)

• Questions/Réponses - Table ronde
  Xavier Mariette, Pierre Tiberghien et Marie-Paule Kieny